Thought Leadership
Status Quo Maintained: FDA Reverses Course on Generic Product Labeling
March 1, 2019
Chad Landmon
FDLI Update

Axinn partner Chad Landmon co-authored the FDLI’s Update article, "Status Quo Maintained: FDA Reverses Course on Generic Product Labeling."

Click here to access the article. Shared with the permission of FDLI.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.